Frans J.M. van Breukelen , Karin Mattson , Giuseppe Giaccone , Nico van Zandwijk , Hans T. Planteydt , Anne Kirkpatrick , Otilia Dalesio
{"title":"Mitoxantrone in malignant pleural mesothelioma: A study by the EORTC lung cancer cooperative group","authors":"Frans J.M. van Breukelen , Karin Mattson , Giuseppe Giaccone , Nico van Zandwijk , Hans T. Planteydt , Anne Kirkpatrick , Otilia Dalesio","doi":"10.1016/0277-5379(91)90430-L","DOIUrl":null,"url":null,"abstract":"<div><p>46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m<sup>2</sup> every 3 weeks. Histology was confirmed by a pathology panel. None of the patients had received previous chemotherapy. Toxicity was mainly mild gastrointestinal and haematological side-effects. Out of 34 patients evaluated for response, only 1 partial response was recorded. Mitoxantrone at this dose and schedule has marginal activity in malignant mesothelioma.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90430-L","citationCount":"46","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190430L","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 46
Abstract
46 patients with malignant pleural mesothelioma were entered in a phase II study of mitoxantrone 14 mg/m2 every 3 weeks. Histology was confirmed by a pathology panel. None of the patients had received previous chemotherapy. Toxicity was mainly mild gastrointestinal and haematological side-effects. Out of 34 patients evaluated for response, only 1 partial response was recorded. Mitoxantrone at this dose and schedule has marginal activity in malignant mesothelioma.